Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Genzyme ships vials of newly produced Cerezyme

Genzyme Corporation announced today that it has begun shipping vials of newly produced Cerezyme® (imiglucerase for injection) manufactured at its Allston Landing plant.

2 Dec 2009

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

Harvest Technologies Corp. announced today results from the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri Ramachandra Medical Center is a Harvard Medical international-associated institution based in Chennai, India and one of the largest private healthcare facilities in South Asia.

2 Dec 2009

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

ASH to host annual High School Student Symposium at New Orleans Marriott

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Pfizer and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease.

1 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

$Stem cell technology for rapid healing of complicated bone fractures$

Stem cell technology for rapid healing of complicated bone fractures

A novel technology involving use of stem cells, developed by Hebrew University of Jerusalem researchers, has been applied to provide better and rapid healing for patients suffering from complicated bone fractures.

30 Nov 2009

High levels of physical activity may damage knees and increase risk for osteoarthritis

Middle-aged men and women who engage in high levels of physical activity may be unknowingly causing damage to their knees and increasing their risk for osteoarthritis, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

Researchers at Uppsala University and University Children's Hospital in Uppsala have devised powerful new tools for typing cells from children with acute lymphatic leukemia and for prediction of how children with leukemia will respond to chemotherapy.

28 Nov 2009

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.

28 Nov 2009

Scientists demonstrate stem cells heal lungs of newborn rats; study anticipated to benefit premature babies

Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.

27 Nov 2009

Wnt signaling pathway plays a role in diabetic retinopathy

A group led by Dr. Jian-xing Ma at The University of Oklahoma Health Sciences Center, Oklahoma City, OK has demonstrated that the Wnt signaling pathway plays a role in diabetic retinopathy.

26 Nov 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

Incyte enters into collaboration and license agreement with Novartis

Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

25 Nov 2009

Shire submits a MAA for velaglucerase alfa in Europe

Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

24 Nov 2009

Bone Marrow News and Research

Further Reading

Genzyme ships vials of newly produced Cerezyme

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

ASH Annual Meeting to showcase latest research and treatments for blood disorders

MRI pioneer honored with MRC Millennium Medal

ASH to host annual High School Student Symposium at New Orleans Marriott

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Amgen to present updated data on Nplate at the 2009 ASH meeting

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Kiadis Pharma commences enrollment in multinational ATIR study

Allos Therapeutics granted U.S. patent for FOLOTYN

Stem cell technology for rapid healing of complicated bone fractures

High levels of physical activity may damage knees and increase risk for osteoarthritis

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

Scientists demonstrate stem cells heal lungs of newborn rats; study anticipated to benefit premature babies

Wnt signaling pathway plays a role in diabetic retinopathy

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Incyte enters into collaboration and license agreement with Novartis

Shire submits a MAA for velaglucerase alfa in Europe

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News